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The emergence of highly aggressive subtypes of human cutaneous squamous cell carcinoma (SCC) often reﬂects increased au-
tocrine/paracrine TGF-β synthesis and epidermal growth factor receptor (EGFR) ampliﬁcation. Cooperative TGF-β/EGFR signal-
ing promotes cell migration and induces expression of both proteases and protease inhibitors that regulate stromal remodeling
resulting in acquisition of an invasive phenotype. TGF-β1+EGF stimulation increases the production of several matrix metal-
loproteinases (MMPs) in human SCC. Among the most prominent is MMP-10 which is known to be elevated in SCC in situ.
Activation of stromal plasminogen appears to be critical in triggering downstream MMP activity. Paradoxically, PAI-1, the major
physiological inhibitor of plasmin generation, is also up-regulated under these conditions and is an early event in progression
of incipient epidermal SCC. A model is proposed in which TGF-β1+EGF-dependent MMP-10 elevation directs focalized matrix
remodeling events that promote epithelial cell plasticity and tissue invasion. Increased PAI-1 expression serves to temporally and
spatially modulate plasmin-initiated pericellular proteolysis, further facilitating epithelial invasive potential. Deﬁning the complex
signalingmechanismsthatmaintainthiselegantbalanceiscriticaltodevelopingpotentialtherapeuticsforthetreatmentofhuman
cutaneous malignancies.
Copyright © 2007 Cynthia E. Wilkins-Port et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. HUMAN EPITHELIAL SKIN CANCER PROGRESSION
Cutaneous cancer is the most common human malignant
disease [1]; in North America alone, >50% of all neoplasms
ariseintheskin[2].Thedevelopment andprogression ofep-
ithelial skin tumors is causally linked to ultraviolet (UV) ra-
diation exposure, with UV-B “signature” base changes (C→T
or CC→TT) frequently mapping to codons 177 (basal cell
carcinoma) and 278 (squamous cell carcinoma (SCC)) in
the tumor suppressor p53 gene [3, 4]. Indeed, UV-associated
p53 mutations regularly occur in the solar radiation-induced
premalignancyactinickeratosis.Approximately10%ofthese
precancerous lesions progress to SCC and it has been esti-
mated that 60% of all SCC arise within actinic keratoses [4–
6].
The progression sequence for cutaneous cancers may
vary between the human disease and its corresponding
mouse models, although several genetic events are common
to both [2, 3, 5–7]. Transition of a normal keratinocyte
to an initiated pre- or early malignant phenotype for ex-
ample often involves p53 inactivation, ras gene mutation
and ampliﬁed ras expression. These changes frequently ac-
company growth of lesional subsets in both actinic kerato-
sis and SCC [5–7]. Recent ﬁndings suggest that the emer-
gence of highly aggressive subtypes of SCC (including the
lethal spindle cell tumor) and the development of metastatic
variants are causally linked to overexpression of transform-
ing growth factor-β1(T G F - β1) [2, 8–10]. Elevated autocrine
and/or paracrine production of TGF-β1, in fact, typiﬁes ad-
vanced pathologies in both mouse and human SCC [8, 10].
Despite high levels of TGF-β in the immediate tumor mi-
croenvironment, at least some malignant epithelial cells be-
come refractory to the normal program of proliferative ar-
rest initiated by TGF-β which is likely a consequence of2 Journal of Biomedicine and Biotechnology
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Figure 1: Genetic events associated with human cutaneous SCC
progression in vivo and in the HaCaT keratinocyte model system
in vitro. Additional similarities are discussed in the text as well as in
[2, 3, 21].
transformation-associated reductions in either TGF-β-RII or
Smad-4 levels, or both [10–12]. In experimental models of
skincarcinogenesis,moreover,resistancetoTGF-β1-induced
growth suppression is often coupled with epidermal growth
factorreceptor(EGFR)ampliﬁcation,particularlyduringthe
later stages of tumor progression [13–17]. Indeed, cutaneous
SCCs frequently exhibit constitutive activation of the EGFR
as a result of receptor ampliﬁcation and/or autocrine ligand
release [18]. The subsequent reprogramming of gene expres-
sion in the transformed keratinocyte initiates and perpetu-
ates the TGF-β1-induced pro-oncogenic switch to a “plastic”
phenotype, resulting in the transition from a relatively indo-
lent to a highly aggressive and invasive epithelial malignancy
[8, 19, 20].
2. DETERMINANTS OF CELLULAR PLASTICITY IN
TRANSFORMED HUMAN KERATINOCYTES
The immortalized adult human keratinocyte cell line
HaCaT-II4 is particularly suited for assessment of molecu-
lar mechanisms associated with epithelial tumor cell plastic-
ity(reviewedin[13]).HaCaT-II4cellsharbormutationsthat
mirror those associated with cutaneous malignant transfor-
mation. These include UV-speciﬁc mutations in both alleles
of the p53 gene (resulting in loss of p53 function [3]), in-
creased levels of an activated Ha-ras gene, and chromosomal
aberrations often typical of SCC (e.g., loss of 3p and 9p, gain
of 3q) [2, 3, 21]( Figure 1).
HaCaT-II4 cell stimulation with a combination of TGF-
β1 and EGF, designed to mimic the elevated TGF-β1e x p r e s -
sion/ampliﬁed EGFR signaling that frequently accompanies
SCC progression in vivo, promotes a phenotypic transition
that involves the loss of E-cadherin from cell-cell junctions,
actin microﬁlament remodeling (Figure 2), increased motil-
ity, and signiﬁcantly enhanced pericellular proteolytic capa-
bility [22, 23].
Stromal proteolysis by transformed keratinocytes is of-
ten initiated by conversion of epidermal matrix plasmino-
gen to the broad-spectrum protease plasmin via urokinase
Quiescent EGF/TGF-β1
E-cadherin/actin E-cadherin/actin
Figure 2: HaCaT-II4 keratinocytes initiate a prominent “scatter-
ing” response after a 24–48 hour exposure to EGF/TGF-β1. Colony
dispersal (top panels) reﬂects the early and signiﬁcant loss of E-
cadherin-positive cell-cell junctions (green) and marked reorgani-
zation in the actin microﬁlament system (red) (bottom panels).
Suchmorphologicrestructuringisahallmarkofepithelial plasticity
initiated by TGF-β and EGF family members.
plasminogen activator receptor (uPAR)-bound uPA [24–26].
Plasmin generation accompanies cooperative TGF-β/EGFR
signaling during epidermal tumor progression and appears
to be a critical event in the downstream activation of a com-
plex and highly interdependent, matrix metalloproteinase
(MMP) cascade (reviewed in [23]). Microarray proﬁling
of HaCaT-II4 cells stimulated with both TGF-β1a n dE G F
conﬁrmed, in fact, that uPA, uPAR, and MMP expres-
sion levels were signiﬁcantly upregulated (e.g., Figure 3).
Transcripts encoding plasminogen activator inhibitor type-
1 (PAI-1; SERPINE1), the major physiological regulator of
plasmin-basedpericellularproteolysis,werealsosigniﬁcantly
increased. Indeed, elevated PAI-1 tumor levels signal a poor
prognosis and reduced disease-free survival in patients with
breast,lung,ovarian,andoralSCC[26,27].Mousemodeling
and genetic studies clearly implicate PAI-1 as an important
determinant in cutaneous tumor invasion and the associated
angiogenic response. This serine protease inhibitor main-
tains an angiogenic “scaﬀold,” stabilizes nascent capillary
vessel structure, and regulates tumor cell invasion through
precise regulation of the peritumor proteolytic microenvi-
ronment [26, 28–30] .P A I - 1u p r e g u l a t i o ni s ,i nf a c t ,a ne a r l y
event in the progression of incipient epidermal SCC, where
it often localizes in tumor cells and myoﬁbroblasts at the
invasive front (Figure 4), and most importantly is a tumor
marker with signiﬁcant prognostic value [27, 31–33]. Fur-
thermore, identiﬁcation of PAI-1 in SCC-proximal stromalCynthia E. Wilkins-Port et al. 3
myoﬁbroblasts implies a more global involvement in mod-
ulating cellular invasive potential, [34–36] with complex au-
tocrineandparacrineloopsdictatingthevariedeﬀectsofthis
SERPIN on individual elements (neoplastic, endothelial, and
inﬂammatory cells) within the tumor microenvironment.
3. GROWTH FACTOR-INITIATED EPITHELIAL
PLASTICITY ELICITS A PROGRAM OF
MATRIX REMODELING
Treatment of HaCaT-II4 cells with TGF-β1a n dE G Fp r o -
motes a plastic transition typical of late-stage SCC progres-
sion (Figure 2). Part of this response most likely reﬂects
thetranscriptionalconsequencesassociatedwithderegulated
growth factor signaling (e.g., Figure 3)[ 37–40]. TGF-
β1 stimulates synthesis of stromal components (e.g., ﬁ-
bronectin, collagen, laminin), thereby supporting the main-
tenance of matrix integrity; this growth factor, however,
also increases expression of several extracellular matrix-
degrading MMPs, including MMP-1, -2, -3, -9, -10, -11,
-13, and 21 [41–47]. Unlike the normal epithelium, where
TGF-β1 upregulates collagen synthesis and represses collage-
nase proteolysis, TGF-β1 usually decreases collagen synthe-
sis and induces collagenase activity in malignant cells, sug-
gestingthattransformedepitheliaexhibitanalteredresponse
to TGF-β1[ 48–51]. EGF stimulation similarly induces ex-
pression of several MMPs [52–54]. Consequently, a TGF-
β1-enriched tumor microenvironment coupled with ampli-
ﬁed EGFR levels and/or signaling correlates strongly with
the increased expression of MMP-2, -7, -9, 10, -11, and -13
[17, 55] and is frequently associated with advanced patho-
logical stages in human SCC. The expression of MMP-10
(stromelysin-2) following costimulation of HaCat-II4 cells
with TGF-β1 and EGF is particularly signiﬁcant [22, 23].
MMP-10 is generally restricted to epithelial cells [46, 56]
and has broad substrate speciﬁcity, including as targets the
proMMPs-1, -7, -8, -9, and -13, collagens types III, IV, and V,
gelatin, elastin, ﬁbronectin, proteoglycans, and laminin [25,
57]. MMP-10 is not detectable in normal intact skin [46]. It
ishowever,expressedduringcutaneousinjuryrepairwhereit
localizes to migrating keratinocytes at the wound edge, sug-
gesting that MMP-10 facilitates invasive behavior [46]. In-
deed,appreciablelevelsofMMP-10areevidentinSCCofthe
head and neck, esophagus, oral cavity, and skin, as well as in
r e c u r r e n c e so fn o n s m a l lc e l ll u n gc a n c e rw h e r ei tl i k e l yr e g u -
lates basement membrane degradation and stromal dissem-
ination [55, 58–64]. Notably, TGF-β1/EGF-dependent up-
regulation of MMP-10 in HaCaT-II4 cells is coincident with
enhanced collagen gel invasion (Figure 5) and the develop-
ment of an acute collagenolytic phenotype that is sensitive to
components of the plasminogen activation system, including
PAI-1 [22, 23]. While the actual involvement of MMP-10 in
late-stage tumor progression remains to be clariﬁed, MMP-
10 can “superactivate” collagenase I (MMP-1) resulting in a
10-fold increase in speciﬁcactivity whencomparedto MMP-
1 activation by plasmin alone [56]. Collectively, these ﬁnd-
ings support a model in which TGF-β1/EGF-initiated MMP-
10upregulationanditsplasmin-dependentactivationleadto
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Figure 3: Example of a selected cluster of TGF-β1+EGF-induced
genes in HaCaT-II4 human SCC cells. PAI-1 is the highest upregu-
lated transcript in the subset illustrated. (13.4-fold assessed 6 hours
after growth factor stimulation). MMP-1 and MMP-2 are also sig-
niﬁcantly increased in response to TGF-β1+EGF as is the uroki-
nase plasminogen activator receptor (uPAR). The 5-fold induction
of uPA mRNA is not shown. Numbers for the individual upregu-
lated expressed genes indicate the fold increase for TGF-β1+EGF-
stimulated cells compared to unstimulated keratinocytes. The col-
orized platform serves to provide a visual indicator of the microar-
raydatawithgreensignalcorrespondingtominimalornonexpress-
ing status while red signal is indicative of high-level transcript in-
duction.
the degradation of extracellular matrix components directly,
as well as indirectly by its ability to trigger MMPs-1, -7, -8,
-9, and -13 activities (Figure 6). Subsequently, these down-
stream proteases target stromal substrates, particularly colla-
gens and additional pro-MMPs in the tumor microenviron-
ment. The resultant feedback loop generated through eleva-
tion of MMP-10 levels therefore supports focalized extracel-
lular matrix remodeling which promotes the acquisition of
cellular plasticity and tumor cell invasion. Most importantly,
this highly interactive plasmin-initiated, pericellular prote-
olytic cascade is ﬁnely “titrated” both temporally and spa-
tially by PAI-1, highlighting the potential therapeutic value
of manipulating PAI-1 expression in the treatment of human
cutaneous malignancies [13, 22, 23, 29, 30, 65].4 Journal of Biomedicine and Biotechnology
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Figure 4: Sections of an early invasive human squamous cell car-
cinoma (SCC) were stained for PAI-1 (red) and α-smooth muscle
actin (green). (a) Demonstrates the localization of PAI-1 at the in-
vasivefrontofthetumor(arrows).(b)(PAI-1),(c)(α-smoothmus-
cle actin), and (d) (merged) illustrate the colocalization of PAI-1
with cells stained positive for α-smooth muscle actin, a marker for
myoﬁbroblasts. Barbed arrows indicate PAI-1/α-SMA at the tumor
perimeter, while arrow heads depict PAI-1/α-SMA in the stroma.
4. TGF-β1/EGFR PATHWAY INTEGRATION IN PAI-1
EXPRESSION CONTROL
Recent studies revealed a more complicated, cooperative in-
teraction between intracellular events orchestrated by TGF-
β1-activated pathways and the EGFR, which speciﬁcally lead
to epithelial tumor plasticity. PAI-1 induction in response to
TGF-β1 involves a complex network of signaling intermedi-
ates and requires the activities of the mitogen-activated ex-
tracellular kinase (MEK), p21ras,a n dp p 6 0 c-src in addition
to the EGFR [66]. pp60c-src is, in fact, a critical interme-
diate in a TGF-β1-initiated transduction cascade leading to
MEK signaling, PAI-1 transcription, and subsequent pheno-
typic responses [66–70]( Figure 7). The src family kinase in-
hibitor PP1 and dominant-negative pp60c-src constructs ef-
fectively attenuate TGF-β1-induced PAI-1 expression in Ha-
CaT cells [66], conﬁrming the generality of src kinase in-
volvement in PAI-1 gene regulation. While the actual mech-
anism underlying TGF-β1-associated pp60c-src kinase stim-
ulation remains to be determined, the TGF-β1-dependent
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Figure 5: HaCaT-II4 cells invade collagen gels following costimula-
tion with TGF-β1 and EGF. HaCaT-II4 or SCC-25 cells were seeded
in serum-free advanced DMEM (GIBCO) onto collagen gels that
had been polymerized in OptiCell tissue culture chambers. Twenty
four hours later, cells were stimulated with a combination of TGF-
β1 (1ng/mL) and EGF (10ng/mL) under serum-free conditions
and allowed to incubate for 48 hours. Pictures were taken at X10
magniﬁcation using an IX70 Olympus microscope and ImagePro-
Plus software.
release of EGFR ligands HB-EGF and/or TGF-α appears to
involve MMP-directed cleavage of EGF-like precursors re-
sulting in EGFR activation [71–73]. Alternatively, forma-
tion of integrin/FAK/p130cas/EGFR complexes in response
to TGF-β1 may result in ligand-independent EGFR mobi-
lization and β increased pp60c-src activity [74–76]. Subse-
quent changes in gene programming likely reﬂect the par-
ticular src-dependent MAP kinase pathways impacted. src ki-
nases, for example, can phosphorylate the raf-1 kinase ei-
ther directly or as part of a CNK1 scaﬀold complex, result-
ing in src-dependent ERK activation [77–79]. Indeed, the ef-
fective blockade of TGF-β1-stimulated ERK1/2 phosphory-
lation and PAI-1 transcription by PP1 as well as the EGFR
inhibitor AG1478 (Figure 7) and the requirement for MEK-
ERKsignalingforthefullinductiveeﬀectofTGF-β1,suggests
that pp60c-src may regulate MEK-ERK-dependent PAI-1 ex-
pression via EGFR activation at the Y845 site [66, 67, 75].
The continued deﬁnition of speciﬁc molecular mecha-
nisms underlying control of tumor progression genes is an
essential element in the ultimate design of targeted, clinicallyCynthia E. Wilkins-Port et al. 5
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Figure 6: Proposed model illustrating the potential eﬀects of TGF-β1/EGF stimulated upregulation of MMP-10 and PAI-1 on premalignant
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Figure 7: The PAI-1 expression control network. TGF-β1 can signal alone to MEK as well as transactivate the EGFR. This cascade requires
the participation of pp60c-src and ras. The downstream-activated MAP kinases (ERKs, p38) phosphorylate, and thereby, regulate the activity
of speciﬁc transcription factors (e.g., members of the USF family) that are known to impact PAI-1 gene control [13]. PAI-1 expression, in
turn, aﬀects cell survival, migration, and matrix remodeling as part of the program of epithelial plasticity. Inhibitors of PAI-1 expression or
function are shown in red and represent potential therapeutic target points.6 Journal of Biomedicine and Biotechnology
relevant, options for treatment of human cutaneous SCC.
Indeed, the emerging appreciation that cooperative EGFR
signaling is an essential aspect of TGF-β1-stimulated PAI-
1 expression provides novel insights to the impact of TGF-
β1 in late-stage human tumor progression and underscores
the potential diversity of new molecular targets that can be
exploited for therapeutic beneﬁt. Reﬁning the current un-
derstanding of PAI-1 gene regulation, as well as its signal-
ingpathways,mayleadtothedesignoftranscription-focused
“therapeutics” to manage human cutaneous malignancies.
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